Loading
A phase 2 trial of furmonertinib, pemetrexed, carboplatin and bevacizumab in lung cancer, run by Sun Yat-sen University, now recruiting.
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA is a phase 2, randomised interventional study registered as NCT05334277 by Sun Yat-sen University, with a registry enrolment figure of 280 participants, started 2022-05-06 and due to reach its primary completion in 2025-02-28. Interventions recorded: Furmonertinib; Furmonertinib; Furmonertinib/Pemetrexed/Carboplatin; Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "Pathologically confirmed non-squamous Non-Small Cell Lung Cancer (NSCLC);". Sites: China. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Furmonertinib, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.